Antônio Luiz Frasson, Ana Beatriz Falcone, Fernanda Barbosa, Alessandra Borba Anton de Souza, Carolina Malhone, Isabela Miranda, Betina Vollbrecht, Monica Adriana Rodriguez Martinez Frasson, Luiza Kobe, Martina Lichtenfels
{"title":"Low rate of complications in nipple-sparing mastectomy for patients with <i>BRCA1</i> and <i>BRCA2</i> mutation.","authors":"Antônio Luiz Frasson, Ana Beatriz Falcone, Fernanda Barbosa, Alessandra Borba Anton de Souza, Carolina Malhone, Isabela Miranda, Betina Vollbrecht, Monica Adriana Rodriguez Martinez Frasson, Luiza Kobe, Martina Lichtenfels","doi":"10.2217/pme-2023-0084","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> To describe the indications and outcomes of <i>BRCA</i> mutation carriers undergoing nipple-sparing mastectomy (NSM). <b>Methods:</b> In this retrospective study, 76 <i>BRCA</i> mutation carriers with no cancer who opted to undergo risk reduction NSM or diagnosed with breast cancer (BC) who opted to undergo therapeutic NSM were included. <b>Results:</b> Indications for NSM: cancer treatment (n = 33), bilateral risk reduction (n = 39) and contralateral prophylactic NSM (n = 4). In a mean follow-up of 45 months (median: 30 months), one patient (2.5%) undergoing risk-reducing NSM developed a new BC. One (3%) local, one (3%) ipsilateral axillary and one (3%) distant recurrence were observed in BC patients. No partial or total nipple necrosis occurred. <b>Conclusion:</b> NSM is safe for reducing the risk of BC development in <i>BRCA</i> mutation carriers and for treating cancer.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"493-501"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/pme-2023-0084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To describe the indications and outcomes of BRCA mutation carriers undergoing nipple-sparing mastectomy (NSM). Methods: In this retrospective study, 76 BRCA mutation carriers with no cancer who opted to undergo risk reduction NSM or diagnosed with breast cancer (BC) who opted to undergo therapeutic NSM were included. Results: Indications for NSM: cancer treatment (n = 33), bilateral risk reduction (n = 39) and contralateral prophylactic NSM (n = 4). In a mean follow-up of 45 months (median: 30 months), one patient (2.5%) undergoing risk-reducing NSM developed a new BC. One (3%) local, one (3%) ipsilateral axillary and one (3%) distant recurrence were observed in BC patients. No partial or total nipple necrosis occurred. Conclusion: NSM is safe for reducing the risk of BC development in BRCA mutation carriers and for treating cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
